Relationship of Prostate Volume and Serum Prostate-specific Antigen with Body Mass Index in Men Over 40 Years Old

Document Type : Original Article


1 Department of Radiology, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Associate Professor of Radiology, Department of Radiology, School of Medicine, Imam Khomeini Hospital, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Assistant Professor of Uro-oncology, Department of Urology, School of Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

4 Assistant Professor of Radiology, Department of Radiology, School of Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran



Background and Objectives Prostate cancer is the second most common cancer in men worldwide and the third leading cause of cancer-related death in men after lung and colon cancer. The present study aimed to assess the relationship of prostate volume and serum prostate-specific antigen (PSA) with body mass index (BMI) in men over 40 years old in Ahvaz.
Subjects and Methods This descriptive-analytical study was conducted on apparently healthy men over 40 years of age. Parameters, such as age, BMI, prostate volume, and PSA level, were checked in all subjects. The relationship between age, BMI, prostate volume, and PSA level in men over 40 was evaluated as prostate cancer diagnosis parameters.
Results The mean age of subjects was 58.61±10.01 years. A significant relationship was observed between BMI and prostate volume (P=0.019), BMI and PSA level (P=0.001), prostate volume and age of patients (P<0.001), and age and PSA level (r=0.821; P<0.001). People with higher BMI had higher mean prostate volume and PSA levels compared to those with lower BMI. An increase in age was significantly associated with increasing prostate volume and PSA level. In general, there was no correlation between prostate volume and PSA level (P=0.37).
Conclusion As evidenced by the results of this hospital study, an increase in age and BMI are positively related to PSA concentration and prostate volume; nonetheless, no correlation was observed between PSA and prostate volume. BMI and age may be better parameters to estimate PSA concentration and prostate volume.


Main Subjects

[1] Organization WH. International Agency for Research on Cancer GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lung Cancer. 2012. [Link]
[2] Gann PH. Risk factors for prostate cancer. Rev Urol. 2002; 4(Suppl 5):S3-S10. [PMID] [PMCID]
[3] Nogueira L, Corradi R, Eastham JA. Prostatic specific antigen for prostate cancer detection. Int Braz J Urol. 2009;35(5):521-9;530-2. [DOI: 10.1590/s1677-55382009000500003] [PMID]
[4] Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-8. [DOI: 10.1056/NEJMsr1606602] [PMID] [PMCID]
[5] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI: 10.3322/caac.21660] [PMID]
[6] Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477. [DOI: 10.1136/bmj.j477] [PMID] [PMCID]
[7] Ylli D, Sidhu S, Parikh T, Burman KD. Endocrine changes in obesity. Endotext [Internet]. 2022. [PMID]
[8] Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Lausanne). 2021;12:554078. [DOI: 10.3389/fendo.2021.554078] [PMID] [PMCID]
[9] Harrison S, Tilling K, Turner EL, Lane J, Simpkin A, Davis M, et al. Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful? Cancer Causes Control. 2016;27(12):1465-74. [DOI: 10.1007/s10552-016-0827-1] [PMID] [PMCID]
[10] Harrison S, Tilling K, Turner EL, Martin RM, Lennon R, Lane J, et al. Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes Control. 2020;31(5):431-49. [DOI: 10.1007/s10552-020-01291-3] [PMID] [PMCID]
[11] Fowke JH, Matthews CE. PSA and body composition by dual X‐Ray absorptiometry (DXA) in NHANES. Prostate. 2010;70(2): 120-5. [DOI: 10.1002/pros.21039] [PMID]
[12] Lin D, Liu T, Chen L, Chen Z. Body mass index in relation to prostate-specific antigen-related parameters. BMC Urol. 2021;21(1):130. [DOI: 10.1186/s12894-020-00746-8] [PMID] [PMCID]
[13] Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008;71(5):787-91. [DOI: 10. 1016/j.urology.2007.11.036] [PMID]
[14] Bonn SE, Sjölander A, Tillander A, Wiklund F, Grönberg H, Bälter K. Body mass index in relation to serum prostate‐specific antigen levels and prostate cancer risk. Int J Cancer. 2016;139(1):50-7. [DOI: 10.1002/ijc.30052] [PMID]
[15] Popovici D, Stanisav C, Pricop M, Dragomir R, Saftescu S, Ciurescu D. Associations between Body Mass Index and Prostate Cancer: The Impact on Progression-Free Survival. Medicina (Kaunas). 2023;59(2):289. [DOI: 10.3390/medicina 59020289] [PMID] [PMCID]
[16] Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity‐related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298(19):2275-80. [DOI: 10.1001/jama.298.19.2275] [PMID]
[17] Grubb III RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009;18(3):748-51. [DOI: 10.1158/ 1055-9965.EPI-08-0938] [PMID]
[18] Zaza MM, Salem TA, Hassanin ISF, Soliman MHA. Effect of body mass index on prostate volume and prostate-specific antigen in men over 50: A cross-sectional study. Urologia. 2023;90(2):224-9. [DOI: 10.1177/03915603231163349] [PMID]
[19] Alcantara-Zapata DE, Thiersch M, Gonzales GF. Association of serum hepcidin with prostate-specific antigen levels in men from high Andean cities of Peru. Int J Health Sci (Qassim). 2023;17(2):28-36. [PMID] [PMCID]
[20] Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Labate AMM, Fabbri R, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991;40(1):101-4. [DOI: 10.1016/0026-0495(91)90199-7] [PMID]
[21] Freedland SJ, Platz EA, Presti Jr JC, Aronson WJ, Amling CL, Kane CJ, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006;175(2):500-4. [DOI: 10.1016/S0022-5347(05)001 62-X] [PMID]
[22] Giovannucci E, Rimm EB, Chute CG, Kawachi I ,Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140(11):989-1002. [DOI: 10.1093/oxford journals.aje.a117206] [PMID]
[23] Porcaro AB, Tafuri A, Sebben M, Processali T, Pirozzi M, Amigoni N, et al. Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection. Minerva Urol Nefrol. 2019;71(5):516-23. [DOI: 10.23736/S0393-2249.19.03401-5] [PMID]
[24] Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St. Sauver JL, Jacobsen SJ, et al. The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev. 2011;20(3):501-8. [DOI: 10.1158/ 1055-9965.EPI-10-1006] [PMID] [PMCID]
[25] Benson M, McMahon D, Cooner W, Olsson C. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol. 1993;11(4):206-13. [DOI: 10.1007/ BF00185070] [PMID]
[26] Omri N, Kamil M, Alexander K, Edmond S, Ariel Z, David K, et al. Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume.
Shojaei S, et al. Prostate-specific Antigen and Body Mass Index JSMJ. 2023; 22(5):???-???
Journal of Medical Sciences
November & December 2024. Vol 22. No 5
Prostate. 2020;80(16):1444-9. [DOI: 10.1002/pros.24078] [PMID]
[27] Coric J, Mujic J, Kucukalic E, Ler D. Prostate-Specific Antigen (PSA) and prostate volume: better predictor of prostate cancer for bosnian and herzegovina men. Open Biochem J. 2015;9:34-6. [DOI: 10.2174/1874091X01509010034] [PMID] [PMCID]
[28] Putra IBO, Hamid AR, Mochtar CA, Umbas R. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. Prostate Int. 2016;4(2):43-8. [DOI: 10.1016/j.prnil.2016.03.002] [PMID]
[29] Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005;40(3):121-8. [DOI: 10.1016/j.exger.2004.12.008] [PMID]
[30] Baruah S, Nath S, Puthenveetil R, Baruah S, Deka P, Bawri B. Correlation of age, prostate volume, serum prostate-specific antigen, and serum testosterone in Indian, benign prostatic hyperplasia patients. UroToday Int J. 2012;5(5):1-6. [DOI: 10.3834/uij.1944-5784.2012.10.02]
[31] Vesely S, Knutson T, Damber J-E, Dicuio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2003;37(4):322-8. [DOI: 10.1080/00365590310014760] [PMID]
[32] Lee SE, Chung JS, Han BK, Moon KH, Hwang SI, Lee HJ, et al. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. Urology. 2008;71(3):395-8. [DOI: 10.1016/j. urology.2007.10.019] [PMID]
[33] Putra IBO, Hamid AR, Mochtar CA, Umbas R. Prostate International. Age (y). 2016;65:7.81.
[34] Liu C-C, Huang S-P, Li W-M, Wang C-J, Chou Y-H, Li C-C, et al. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology. 2007;70(4):677-80. [DOI: 10.1016/j.urology.2007.05.025] [PMID]
[35] Briganti A, Capitanio U, Suardi N, Gallina A, Salonia A, Bianchi M, et al. Benign prostatic hyperplasia and its aetiologies. European Urology Supplements. 2009;8(13):865-71. [DOI: 10.1016%2Fj.eursup.2009.11.002 ]
[36] Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia (BPH). BJU Int. 2008;102(5):536-44. [DOI: 10.1111/j.1464-410X.2008. 07667.x] [PMID]
[37] Payne H, Cornford P, editors. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol. 2011;29(6):593-601. [DOI: 10.1016/j.urolonc.2009.11.003] [PMID]
[38] Lieber MM, Jacobsen SJ, Roberts RO, Rhodes T, Girman CJ. Prostate volume and prostate‐specific antigen in the absence of prostate cancer: A review of the relationship and prediction of long‐term outcomes. Prostate. 2001;49(3):208-12. [DOI: 10.1002/pros.1136] [PMID]